Caption Management’s 10x Genomics TXG Stock Holding History

Caption Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-16,000	Closed	-$1.22M	–	1843
2022 Q1	$1.22M	Buy	+16,000	New	+$1.4M	0.01%	907

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caption Management's TXG Position: Q4 2024 in Review

Caption Management sold out of 10x Genomics (TXG) in Q4 2024, closing a stake of 3,000 shares — an estimated $67.7K sold.

Caption Management first reported a position in TXG in Q1 2022 and held it in 2 quarters. The position peaked at $265K in Q1 2022. 273 funds tracked by Wall St. Rank hold TXG as of Q4 2024.

Caption Management reported no remaining 10x Genomics position as of Q4 2024 after selling out during the quarter.
Caption Management sold 3,000 10x Genomics shares in Q4 2024, an estimated $67.7K.
Caption Management first reported a position in 10x Genomics in Q1 2022 and held it in 2 quarters.
Caption Management's 10x Genomics position peaked at $265K in Q1 2022.
273 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2024.

Based on Caption Management's 13F filing for Q4 2024, filed 14 Feb 2025.